α7 Nicotinic Acetylcholine Receptor-Reference-Cited by-同舟云学术

α7 Nicotinic Acetylcholine Receptor

Published:2018-06 Issue:3 Volume:38 Page:247-249
ISSN:1533-712X
Container-title:Journal of Clinical Psychopharmacology
language:en
Short-container-title:J Clin Psychopharmacol

Author:

Jones Candace

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Psychiatry and Mental health

Reference21 articles.

1. Harnessing cognitive neuroscience to develop new treatments for improving cognition in schizophrenia: CNTRICS selected cognitive paradigms for animal models;Neurosci Biobehav Rev,2013

2. Dementia praecox redux: a systematic review of the nicotinic receptor as a target for cognitive symptoms of schizophrenia;J Psychopharmacol,2015

3. nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: current trends and perspectives;Schizophr Res,2016

4. α7 Nicotinic acetylcholine receptors and their role in cognition;Brain Res Bull,2013

5. The 15q13.3 deletion syndrome: deficient α7-containing nicotinic acetylcholine receptor–mediated neurotransmission in the pathogenesis of neurodevelopmental disorders;Prog Neuropsychopharmacol Biol Psychiatry,2015

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Repetitive Transcranial Magnetic Stimulation for Working Memory Deficits in Schizophrenia: A Systematic Review of Randomized Controlled Trials;Neuropsychiatric Disease and Treatment;2024-03

2. Dequalinium chloride is an antagonists of α7 nicotinic acetylcholine receptors;European Journal of Pharmacology;2022-06

3. N-methyl-D-aspartate receptor antagonism impairs sensory gating in the auditory cortex in response to speech stimuli;Psychopharmacology;2022-03-28

4. New Strategies to Improve Cognitive Symptom Domain in the Treatment of Schizophrenia;Psychosis and Personality Disorders;2022

5. Sex differences in P50 inhibition defects with psychopathology and cognition in patients with first-episode schizophrenia;Progress in Neuro-Psychopharmacology and Biological Psychiatry;2021-12